Clinical Trial Update: Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer [Phase 3]

View source ↗

Summary

The TEACH Phase 3 trial comparing lapatinib (Tykerb) to placebo in women with early-stage breast cancer has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tykerb (lapatinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Breast | Phase 3 | Status: COMPLETED | Results posted: 2014-08-18